BioNTech SE (NASDAQ:BNTX) Receives Consensus Rating of “Moderate Buy” from Brokerages

BioNTech SE (NASDAQ:BNTX) has earned an average recommendation of “Moderate Buy” from the eighteen brokerages that are currently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $143.73.

BNTX has been the topic of several research reports. Truist Financial assumed coverage on shares of BioNTech in a research report on Friday, January 10th. They issued a “buy” rating and a $172.00 price target on the stock. Wells Fargo & Company started coverage on shares of BioNTech in a report on Wednesday, December 11th. They set an “overweight” rating and a $170.00 target price on the stock. Morgan Stanley cut their price target on BioNTech from $145.00 to $139.00 and set an “overweight” rating for the company in a report on Tuesday, March 11th. Canaccord Genuity Group reiterated a “buy” rating and issued a $171.44 price target on shares of BioNTech in a research report on Tuesday, March 11th. Finally, Citigroup began coverage on BioNTech in a report on Thursday, March 13th. They set a “buy” rating and a $145.00 price objective on the stock.

BioNTech Trading Down 4.1 %

NASDAQ:BNTX opened at $91.06 on Tuesday. BioNTech has a 12 month low of $76.53 and a 12 month high of $131.49. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The firm’s 50 day moving average is $110.99 and its 200 day moving average is $113.65. The stock has a market capitalization of $21.85 billion, a PE ratio of -43.36 and a beta of 0.30.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.70. The firm had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business’s revenue was down 19.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.90 earnings per share. Sell-side analysts expect that BioNTech will post -3.88 earnings per share for the current year.

Hedge Funds Weigh In On BioNTech

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Jones Financial Companies Lllp grew its position in BioNTech by 110.3% during the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock worth $53,000 after acquiring an additional 246 shares during the last quarter. Quintet Private Bank Europe S.A. increased its position in shares of BioNTech by 823.5% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock valued at $88,000 after acquiring an additional 700 shares during the period. Allianz SE bought a new position in shares of BioNTech during the fourth quarter valued at about $90,000. GAMMA Investing LLC boosted its holdings in shares of BioNTech by 48.2% during the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock worth $105,000 after purchasing an additional 300 shares during the period. Finally, Generali Investments CEE investicni spolecnost a.s. bought a new stake in shares of BioNTech in the fourth quarter worth about $137,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.